Does Lacosamide Carry Heart Risks?
Lacosamide, an antiepileptic drug sold as Vimpat, can worsen preexisting heart conditions, particularly those involving conduction abnormalities or rhythm issues. It prolongs the PR interval on ECGs, which slows electrical signals from the atria to ventricles, raising risks for atrioventricular (AV) block. Clinical trials showed PR interval increases of 2-7 milliseconds on average, with higher doses linked to more pronounced effects.[1][2]
Which Heart Conditions Are Most Affected?
Patients with sick sinus syndrome, second- or third-degree AV block, or severe bradycardia face heightened risks. The drug's sodium channel-blocking action can exacerbate these, potentially leading to syncope or cardiac arrest. It's contraindicated in those with these conditions unless a pacemaker is present. Atrial fibrillation or flutter patients may see worsened conduction delays.[3][4]
What Do Studies and Trials Show?
In pivotal trials for partial-onset seizures, 0.5% of lacosamide users (vs. 0% placebo) developed first-degree AV block; higher rates occurred in cardiac subgroups. Post-marketing data reports rare cases of atrial fibrillation, flutter, and ventricular tachycardia. A 2019 review in Epilepsy Research noted dose-dependent PR prolongation, advising ECG monitoring in at-risk patients.[2][5]
How Is It Dosed and Monitored for Heart Patients?
Start at 100 mg/day (50 mg twice daily), titrating slowly to 200-400 mg/day. For heart disease, use lowest effective dose with baseline and follow-up ECGs, especially at 200 mg/day or higher. Avoid in severe hepatic/renal impairment, which amplifies effects. Heart rate below 50 bpm warrants caution.[1][3]
What Are Patient-Reported Heart Side Effects?
Common cardiac effects include dizziness (from conduction issues), palpitations, and fatigue. Serious events like AV block or sudden death are rare (<0.1%) but prompt FDA warnings. Patients with coronary artery disease or heart failure report more arrhythmias; monitor for symptoms like fainting or irregular pulse.[4][6]
Can It Interact with Heart Medications?
Lacosamide has minimal CYP interactions but prolongs PR interval additively with beta-blockers, calcium channel blockers (e.g., diltiazem), or digoxin. Avoid combining with other sodium channel blockers like carbamazepine. Check QT prolongation risk with antiarrhythmics.[3][7]
[1]: Vimpat Prescribing Information (UCB, 2023)
[2]: FDA Label for Lacosamide (DailyMed)
[3]: Epilepsia Journal Review on Lacosamide Cardiac Safety (2018)
[4]: Drugs.com Lacosamide Side Effects
[5]: Epilepsy Research: Dose-Dependent PR Prolongation (2019)
[6]: Medscape Lacosamide Monitoring
[7]: Lexicomp Drug Interactions for Lacosamide